Regulatory framework for bringing proteomic IVDs to patients on cards in US
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration is looking into how to develop a regulatory framework for validating research-level proteomic assays into in vitro diagnostics (IVDs) that can be used with patients in clinical practice1.